Dyne Therapeutics, Inc. (DYN) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US26818M1080
Dyne Therapeutics, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Operating income | -468.18 m USD |
| EBIT | -446.21 m USD |
| Net income | -446.21 m USD |
| Diluted EPS – continuing operations | -3.47 USD |
Full history since 2007, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Dyne Therapeutics, Inc.
Dyne Therapeutics, Inc., a clinical-stage neuromuscular disease company, focuses on discovering and developing therapeutics for neuromuscular diseases in the United States. The company is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; facioscapulohumeral dystrophy; and Pompe disease, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. Dyne Therapeutics, Inc. was incorporated in 2017 and is headquartered in Waltham, Massachusetts.
More stocks
- FangDa Carbon New Material Co Ltd (600516.SS)
- Construcciones y Auxiliar de Ferrocarriles SA (CAF.MC)
- Shanghai M&G Stationery Inc (603899.SS)
- Cellebrite DI Ltd (CLBT)
- Aris Mining Corporation (ARIS.TO)
- Acer Inc (2353.TW)
- Keda Clean Energy Co Ltd (600499.SS)
- CALIFORNIA WATER SERVICE GROUP (CWT)
- Asset World Corp Public Company Limited (AWC.BK)
- Bumi Resources Tbk (BUMI.JK)
- Unite Group PLC (UTG.L)
- Zhejiang Jiemei Electronic and Technology Co Ltd (002859.SZ)
Not investment advice. All data without warranty, price as of 21.10.2026. Details in the risk notice.